PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
EDIT vs. PACB
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

EDIT vs. PACB

Last updated Apr 26, 2025

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EDIT or PACB.

Correlation

The correlation between EDIT and PACB is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

-0.50.00.51.0
Correlation: 0.4

Performance

EDIT vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.
-95.00%-90.00%-85.00%-80.00%NovemberDecember2025FebruaryMarchApril
-91.54%
-91.19%
EDIT
PACB

Key characteristics

Sharpe Ratio

EDIT:

-0.56

PACB:

-0.23

Sortino Ratio

EDIT:

-0.79

PACB:

0.43

Omega Ratio

EDIT:

0.91

PACB:

1.04

Calmar Ratio

EDIT:

-0.73

PACB:

-0.26

Martin Ratio

EDIT:

-1.32

PACB:

-0.79

Ulcer Index

EDIT:

54.43%

PACB:

32.58%

Daily Std Dev

EDIT:

127.59%

PACB:

110.72%

Max Drawdown

EDIT:

-98.92%

PACB:

-97.87%

Current Drawdown

EDIT:

-98.30%

PACB:

-97.87%

Fundamentals

Market Cap

EDIT:

$134.77M

PACB:

$348.49M

EPS

EDIT:

-$2.88

PACB:

-$1.55

PEG Ratio

EDIT:

0.00

PACB:

-0.17

PS Ratio

EDIT:

4.17

PACB:

2.26

PB Ratio

EDIT:

1.00

PACB:

0.69

Total Revenue (TTM)

EDIT:

$31.18M

PACB:

$115.20M

Gross Profit (TTM)

EDIT:

$28.16M

PACB:

$26.00M

EBITDA (TTM)

EDIT:

-$164.01M

PACB:

-$319.24M

Returns By Period

In the year-to-date period, EDIT achieves a 21.26% return, which is significantly higher than PACB's -40.44% return.

EDIT

YTD

21.26%

1M

21.26%

6M

-51.57%

1Y

-70.50%

5Y*

-42.81%

10Y*

N/A

PACB

YTD

-40.44%

1M

-14.17%

6M

-38.42%

1Y

-21.01%

5Y*

-19.52%

10Y*

-15.11%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Risk-Adjusted Performance

EDIT vs. PACB — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
EDIT
The Risk-Adjusted Performance Rank of EDIT is 1616
Overall Rank
The Sharpe Ratio Rank of EDIT is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of EDIT is 1717
Sortino Ratio Rank
The Omega Ratio Rank of EDIT is 1919
Omega Ratio Rank
The Calmar Ratio Rank of EDIT is 88
Calmar Ratio Rank
The Martin Ratio Rank of EDIT is 1515
Martin Ratio Rank
PACB
The Risk-Adjusted Performance Rank of PACB is 4141
Overall Rank
The Sharpe Ratio Rank of PACB is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of PACB is 5050
Sortino Ratio Rank
The Omega Ratio Rank of PACB is 4747
Omega Ratio Rank
The Calmar Ratio Rank of PACB is 3535
Calmar Ratio Rank
The Martin Ratio Rank of PACB is 3434
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. PACB - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The chart of Sharpe ratio for EDIT, currently valued at -0.56, compared to the broader market-2.00-1.000.001.002.003.00
EDIT: -0.56
PACB: -0.23
The chart of Sortino ratio for EDIT, currently valued at -0.79, compared to the broader market-6.00-4.00-2.000.002.004.00
EDIT: -0.79
PACB: 0.43
The chart of Omega ratio for EDIT, currently valued at 0.91, compared to the broader market0.501.001.502.00
EDIT: 0.91
PACB: 1.04
The chart of Calmar ratio for EDIT, currently valued at -0.73, compared to the broader market0.001.002.003.004.005.00
EDIT: -0.73
PACB: -0.26
The chart of Martin ratio for EDIT, currently valued at -1.32, compared to the broader market-5.000.005.0010.0015.0020.00
EDIT: -1.32
PACB: -0.79

The current EDIT Sharpe Ratio is -0.56, which is lower than the PACB Sharpe Ratio of -0.23. The chart below compares the historical Sharpe Ratios of EDIT and PACB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-1.20-1.00-0.80-0.60-0.40-0.20NovemberDecember2025FebruaryMarchApril
-0.56
-0.23
EDIT
PACB

Dividends

EDIT vs. PACB - Dividend Comparison

Neither EDIT nor PACB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. PACB - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, roughly equal to the maximum PACB drawdown of -97.87%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB. For additional features, visit the drawdowns tool.

-99.00%-98.00%-97.00%-96.00%-95.00%NovemberDecember2025FebruaryMarchApril
-98.30%
-97.87%
EDIT
PACB

Volatility

EDIT vs. PACB - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 33.31% compared to Pacific Biosciences of California, Inc. (PACB) at 30.98%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

20.00%40.00%60.00%80.00%NovemberDecember2025FebruaryMarchApril
33.31%
30.98%
EDIT
PACB

Financials

EDIT vs. PACB - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Pacific Biosciences of California, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

Values in USD except per share items